George Medicines, a late-stage biopharma company, in partnership with Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma, developed WIDAPLIK, a new drug for treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure. The US Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025.

WIDAPLIK is a single pill combination of three medicines, telmisartan, amlodipine, and indapamide, for the treatment of hypertension, developed in three doses (10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg strengths), including two doses that are lower than those currently available in single pill combinations.

It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the established safety profile of its three component antihypertensive medications.

George Medicines and Piramal Pharma Solutions began their collaboration on WIDAPLIK in December 2018, when the formulation was developed at Piramal's Pharmaceutical Development site in Ahmedabad, India.

In June 2020, the project was transferred to Piramal's drug product facility in Pithampur, India for validation and manufacturing. Leveraging Piramal's vast technical expertise and extensive experience advancing innovations, George Medicines achieved FDA approval for WIDAPLIK this year.

The success of this endeavour underscores the advantages of Piramal's integrated approach to drug development. By leveraging the expertise and specialised capabilities of each facility involved in the project, Piramal Pharma Solutions and George Medicines developed WIDAPLIK with remarkable efficiency. This accomplishment will help enable patients worldwide to access this new treatment, furthering Piramal Pharma Solutions' mission to reduce the global burden of disease.

Peter DeYoung, CEO, Piramal Global Pharma, said, “We are excited to deepen our collaboration with George Medicines, expanding access to transformative treatment options like WIDAPLIK to support our mission and enhance patient outcomes on a global scale.”

Mark Mallon, CEO, George Medicines said, “Our strategic partnership with Piramal Pharma Solutions has been an important part of the success to date of WIDAPLIK. Globally, more than one billion adults have hypertension, and it remains a major cause of premature death worldwide. With its triple combination efficacy, multiple dosing options, including two doses that are lower than those currently available in single pill combinations, and its established safety profile, WIDAPLIK has the potential to change the hypertension treatment paradigm.”